Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
On May 14, 2025, Dr. Reddy’s Laboratories announced its management’s participation in a series of investor conferences organized by Ambit Capital. These meetings, scheduled from May 20 to May 23, 2025, will take place in Boston, New York, and Chicago, providing an opportunity for the company to engage with institutional investors and discuss potential business developments. This engagement reflects Dr. Reddy’s ongoing efforts to strengthen its investor relations and enhance its visibility in the global pharmaceutical industry.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and production of generic medications, active pharmaceutical ingredients, and over-the-counter products, with a strong focus on global markets.
Average Trading Volume: 2,191,786
Technical Sentiment Signal: Buy
Current Market Cap: $11.72B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.